Complete Conference Management 9th Annual Symposium Contemporary Management of Cardiovascular Disease in Women 2026
Cardiovascular Disease in Women | Women’s Heart Health | Sex-Specific Cardiovascular Risk | Preventive Cardiology | Patient-Centered Cardiovascular Care
The Complete Conference Management 9th Annual Symposium Contemporary Management of Cardiovascular Disease in Women 2026 provides an evidence-based review of cardiovascular prevention, diagnosis, and treatment in women. The program emphasizes how sex-specific risk factors, clinical presentations, and differences in care can influence cardiovascular assessment and management.
Through expert presentations, case-based discussions, and practical clinical applications, the symposium connects emerging evidence with everyday patient care. Its educational focus extends beyond recognizing cardiovascular disease to improving risk assessment, supporting earlier diagnosis, addressing disparities, and developing individualized treatment strategies for women across their lifespan. Women’s CV DLA
Course Details
| Detail | Information |
|---|---|
| Conference Management | Complete Conference Management |
| Symposium Edition | 9th Annual |
| Program Year | 2026 |
| Original Event Date | September 26, 2026 |
| Original Event Format | Hybrid: in-person and online participation |
| Original Venue | Millennium Biltmore Hotel, Los Angeles, California |
| Supporting Institution | PIH Health Good Samaritan Hospital |
| Primary Specialty | Cardiology |
| Educational Focus | Sex-specific cardiovascular prevention, diagnosis, treatment, and patient-centered care |
The organizer confirms the symposium’s edition, date, and venue; the registration information identifies the original activity as a hybrid event. CCM Meetings
Target Audience
This program has been designed to provide primary care physicians, internists, cardiologists, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare providers with the necessary information to increase knowledge and awareness of cardiovascular disease in women with the goal of improving patient care. Women’s CV DLA
Program Overview
The symposium brings together prevention, diagnostic assessment, pharmacological treatment, and cardiovascular interventions within a women-focused clinical framework.
Its scope includes cardiovascular risk assessment, lipid management, hormonal considerations, heart failure, atrial fibrillation, cardiomyopathies, and structural heart disease. The program also examines cardiovascular–kidney–metabolic disease and uses clinical cases to explore treatment decisions involving coronary disease and advanced interventions.
This combination connects the work of primary care clinicians and cardiovascular specialists, emphasizing the recognition of sex-specific differences without separating those considerations from the broader management of cardiovascular disease. Women’s CV DLA
Main Objective
The objective of this symposium is to educate healthcare providers on gender-specific approaches in prevention, diagnosis, and treatment of women with a broad range of cardiovascular diseases. Women’s CV DLA
Learning Objectives
By the end of the symposium participants will be able to:
- Identify sex-specific risk factors and clinical presentations associated with cardiovascular disease in women.
- Apply current evidence-based guidelines for the prevention, diagnosis, and management of cardiovascular disease in women across their lifespan.
- Develop patient-centered strategies to improve cardiovascular risk assessment, education, and outcomes for women in diverse clinical settings. Women’s CV DLA
Needs Assessment
Cardiovascular disease (CVD) is the leading cause of death among women, yet it continues to be under-recognized, under-diagnosed, and under-treated. Women often present with atypical symptoms and have unique risk factors related to pregnancy, menopause, autoimmune disorders, and hormonal changes that may delay diagnosis and treatment. Healthcare professionals require updated knowledge on sex-specific cardiovascular risk assessment, evidence-based prevention strategies, and current treatment guidelines to improve early recognition, reduce disparities in care, and optimize outcomes for women with cardiovascular disease. Women’s CV DLA
Official Program Coverage
The following tables summarize the organizer’s scheduled topics rather than reproduce the lecture titles verbatim. They are not a verified inventory of the MedicalAmboss recordings. Full faculty names appear below.
Morning Program
| Topic Summary | Speaker |
|---|---|
| Women cardiologists: evidence, equity, excellence | Economides; Zhiroff |
| Obesity, heart failure, and GLP-1 agonists | Kittleson |
| Earlier pulmonary arterial hypertension diagnosis and treatment | Oudiz |
| Postmenopausal hormone therapy: safety and labeling | Wei |
| Earlier intervention under 2026 dyslipidemia guidance | Watson |
| Atrial fibrillation ablation outcomes in women | Sureddi |
| 2026 acute pulmonary embolism guidance: sex differences | Megowan |
| Lifetime aortic stenosis management | Zhiroff |
| Tricuspid valve device-therapy selection | Burstein |
These topics appear in the organizer’s morning agenda. Women’s CV DLA
Afternoon Program
| Topic Summary | Speaker |
|---|---|
| 2026 women’s cardiovascular disease update | Economides |
| Cardiovascular–kidney–metabolic syndrome treatment | Economides |
| Cardiac amyloidosis diagnosis and treatment | Rahman |
| Peripartum cardiomyopathy: improved ejection fraction, recovery or remission? | Elkayam |
| Women’s hypertrophic cardiomyopathy: prevalence, presentation; medical versus invasive treatment | Rahman; Zhiroff |
| Coronary disease vignettes: drug-coated balloons; intravascular lithotripsy; mechanical circulatory support for high-risk PCI; ischemic cardiomyopathy revascularization | Economides; Zhiroff — moderators |
Four Q&A periods and opening/closing remarks complement the lectures. Women’s CV DLA
Separately Identified Non-CME Product Theatres
| Session Summary | Speaker / Supporter |
|---|---|
| Breakfast: finerenone (KERENDIA), heart failure with LVEF >40% | Payal Kohli, MD, FACC / Bayer |
| Lunch: hereditary transthyretin amyloidosis with polyneuropathy | Dr. Vasvi Singh / AstraZeneca |
The organizer labels both product theatres Non-CME. Women’s CV DLA
Major Topics Covered
The principal educational themes are women’s cardiovascular risk assessment, preventive cardiology, lipid management, hormone-related cardiovascular considerations, heart failure, arrhythmias, cardiomyopathies, structural heart disease, coronary interventions, and cardiovascular–kidney–metabolic health.
Across these areas, the program emphasizes the relationship between sex-specific clinical differences, treatment selection, and equitable cardiovascular care. Women’s CV DLA
Course Director
Christina Economides, MD, MM, FSCAI
The official faculty page identifies Dr. Economides as Program Director and lists her leadership of the STEMI Receiving Center and Women’s Cardiovascular Health Program at PIH Health Good Samaritan Hospital, Los Angeles. Women’s CV DLA
Faculty
| Faculty Member | Listed Institutional Affiliation |
|---|---|
| Steven Burstein, MD, FACC | PIH Health Good Samaritan Hospital |
| Uri Elkayam, MD, FACC | University of Southern California, Keck School of Medicine |
| Michelle Kittleson, MD, PhD | Smidt Heart Institute, Cedars-Sinai |
| Nichelle Megowan, MD | Harbor-UCLA Medical Center |
| Ronald Oudiz, MD, FACC, FCCP | Harbor-UCLA Medical Center; David Geffen School of Medicine at UCLA |
| Joseph Rahman, MD | PIH Health Good Samaritan Hospital |
| Ravi Sureddi, MD | PIH Health Good Samaritan Hospital |
| Karol Watson, MD, PhD, FACC | David Geffen School of Medicine at UCLA |
| Janet Wei, MD, FACC | Cedars-Sinai Smidt Heart Institute |
| Katrine Zhiroff, MD, FACC, FSCAI | PIH Health Downey Hospital |
These names and affiliations are listed in the symposium’s official faculty directory. Women’s CV DLA
Why This Course Is Relevant
For primary care clinicians and internists, the symposium connects cardiovascular risk assessment with the recognition of clinical presentations that may otherwise be overlooked. Its patient-centered objectives emphasize prevention, education, and the coordination of care.
For cardiologists and multidisciplinary cardiovascular teams, the program places women-specific considerations within a broad diagnostic and therapeutic framework. The educational emphasis is on applying evidence while remaining attentive to differences in presentation, individual risk, and access to appropriate treatment.
For nurses, advanced practice providers, and pharmacists, its focus on risk recognition, patient education, and collaborative management aligns with the needs of teams caring for women in diverse clinical settings. These applications reflect the course’s stated audience and educational objectives. Women’s CV DLA
Original Activity Accreditation
The original symposium was approved for up to 6.5 Live AAFP Prescribed credits, with approval covering September 26, 2026. That accreditation applies to eligible participation in the organizer’s activity; it does not establish that separately purchased MedicalAmboss materials include CME credit or a certificate. Women’s CV DLA
Related Learning on MedicalAmboss
For additional women-focused cardiovascular education, explore Houston Methodist Heart of a Woman: Strategies for Treating and Preventing Heart Disease in Women 2026 and Scripps 5th Annual Scripps Arrhythmias and Cardiomyopathy in Women Symposium 2025. Medical Amboss
Short Description
<div style="border:2px solid #0f766e;border-left:6px solid #0f766e;border-radius:10px;background:#f0fdfa;padding:16px 18px;color:#153e4b;line-height:1.7;">
<p style="margin:0 0 10px;">
<strong>Evidence-based cardiovascular care for women</strong>
</p>
<p style="margin:0;">
Complete Conference Management 9th Annual Symposium Contemporary
Management of Cardiovascular Disease in Women 2026 focuses on
sex-specific risk factors, clinical presentation, prevention,
diagnosis, and treatment. Expert presentations and case-based
discussions connect cardiovascular evidence with practical,
patient-centered care. Designed for primary care physicians,
internists, cardiologists, nurse practitioners, physician assistants,
nurses, pharmacists, and other healthcare providers seeking to
strengthen the recognition and management of cardiovascular
disease in women.
</p>
</div>
+ Topics:
Saturday, September 26, 2026
7:00am Registration/Visit Exhibits
7:15-7:45 Coffee Convocation Lecture The State of Women Cardiologists: Evidence, Equity, and Excellence Christina Economides, MD, MM, FSCAI Katrine Zhiroff, MD, MBA, FACC, FSCAI
7:45-8:45 Breakfast – Product Theatre (Non-CME) The Next Beat: KERENDIA (Finerenone) for Your Patients with Heart Failure (HF) with Left Ventricular Ejection Fraction (LVEF) >40% Speaker: Payal Kohli, MD, FACC Supported by: Bayer
8:45-8:55 Visit Exhibits
8:55-9:00 Welcome and Introductory Remarks Christina Economides, MD, MM, FSCAI
9:00-9:20 Intersection of Obesity and Heart Failure: Role of GLP1 Agonists Michelle Kittleson, MD, PhD
9:20-9:40 Pulmonary Arterial Hypertension (PAH): Call to Action for Early Diagnosis and Treatment Ronald Oudiz, MD
9:40-10:00 FDA Black Box Warning Removed: Changing Perspective on Safety of HRT in Postmenopausal Women Janet Wei, MD, FACC
10:00-10:20 Earlier Intervention: 2026 Dyslipidemia Guidelines Karol Watson, MD, PhD, FACC
10:20-10:30 Question & Answer
10:30-10:40 Break/Visit Exhibits
10:40-11:00 Atrial Fibrillation Ablation: Outcomes in Women Ravi Sureddi, MD
11:00-11:20 2026 Acute PE Guidelines: Sex Differences in Prevalence, Presentation and Treatment Nichelle Megowan, MD
11:20-11:40 Lifetime Management of Aortic Stenosis Katrine Zhiroff, MD, MBA, FACC, FSCAI
11:40-12:00 Tricuspid Valve: Identifying Candidates for Advanced Device Therapies Steven Burstein, MD
12:00-12:10 Question & Answer
12:10-1:10 Lunch – Product Theatre (Non-CME) Unmasking hATTR Polyneuropathy Speaker: Dr. Vasvi Singh Supported by: AstraZeneca
1:10-1:20 Break/Visit Exhibits
1:20-1:35 Cardiovascular Disease in Women: 2026 Update Christina Economides, MD, MM, FSCAI
1:35-1:50 Treatment of Cardiovascular-Kidney-Metabolic (CKM) Syndrome Christina Economides, MD, MM, FSCAI
1:50-2:10 Clinical Approach to the Diagnosis and Treatment of Cardiac Amyloidosis Joseph Rahman, MD
2:10-2:30 Peripartum Cardiomyopathy with Improved EF: A Recovery or Remission Uri Elkayam, MD, FACC
2:30-3:00 Hypertrophic Cardiomyopathy in Women, Prevalence and Presentation New Therapeutic Approach: Invasive versus Medical Evidence and Clinical Experience Joseph Rahman, MD Katrine Zhiroff, MD, MBA, FACC, FSCAI
3:00-3:10 Question & Answer
3:10-3:20 Break/Visit Exhibits
3:20-4:10 Vignettes: Clinical Decision-Making for Coronary Artery Disease Drug-Coated Balloon Angioplasty
- Intravascular Lithotripsy for Calcified CAD in Women
- Mechanical Circulatory Support for High-Risk PCI
- Revascularization in Ischemic Cardiomyopathy
Moderators:
Christina Economides, MD, MM, FSCAI
Katrine Zhiroff, MD, MBA, FACC, FSCAI
4:10-4:25 Question & Answer
4:25-4:30 Closing Remarks
4:30 Adjourn



